Accessibility Menu
LianBio logo

LianBio(OTC) LIANY

Current Price$0.08
Market Cap$8.73MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)+20%
5 YearN/A
1 Year+45%
1 Month-28%
LianBio last closing stock price
MetricPriceDate
Last closeUSD 0.082026-07-20
LianBio stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-27.67%USD 0.112026-07-13
1 month-27.67%USD 0.112026-06-18
3 month-38.08%USD 0.132026-04-21
Year to date-15.79%USD 0.102025-12-31
1 year+45.45%USD 0.062025-07-18
3 year-5.78%USD 0.082023-07-21
Since inception+20.07%USD 0.072021-11-01

LianBio Financials at a Glance

Market Cap

$8.73MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

$314.03M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$0.08

Volume

10,029

Open

$0.07

Previous Close

$0.08

Daily Range

$0.07 - $0.08

52-Week Range

$0.05 - $0.18

Estimated Earnings Date

Aug 18, 2026

LIANY News

A piggybank launching like a rocket.

Why LianBio Stock Is Shooting Through the Roof This Week

Keith NoonanOct 27, 2023
Scientists, Asian

Why LianBio Stock Is Skyrocketing Today

Keith SpeightsOct 24, 2023

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About LianBio

LianBio is a biopharmaceutical firm focused on advancing and commercializing medical treatments for various conditions, including cardiovascular, oncological, respiratory, ophthalmic, and inflammatory diseases. The company primarily operates in China and other Asian markets, with a robust pipeline of investigational therapies.

Products and Services
  • Mavacamten for hypertrophic cardiomyopathy and heart failure
  • TP-03, an eye solution for Demodex blepharitis
  • NBTXR3, targeting head and neck squamous cell carcinoma
Growth Outlook
  • Strategic alliances with Tarsus Pharmaceuticals and Nanobiotix enhance development capabilities
  • Focus on expanding market presence in Asia, particularly China
  • Pipeline includes multiple therapies addressing significant unmet medical needs
Financial Highlights
  • Recent quarterly net income of -$24.04 million, reflecting ongoing R&D investments
  • Cash and short-term investments totaled $252.22 million as of September 30, 2023
  • Trailing twelve-month dividend yield of 5.375%, indicating potential shareholder returns
LianBio's commitment to developing innovative therapies positions the company as a key player in the biopharmaceutical industry. The strategic partnerships and a diverse pipeline of products are expected to drive future growth. Despite recent financial losses, the substantial cash reserves provide a buffer for continued research and development efforts. The focus on addressing critical health issues in Asia presents significant market opportunities, making LianBio an intriguing option for investors interested in the biotechnology sector.
AI Generated • Jul 21, 2026

Industry

Biotechnology

Sector

Health Care

Employees

163

CEO

Adam Leo Stone

Website

www.lianbio.com

Headquarters

Princeton, NJ 08540, US

LIANY Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

11.78%

Return on Capital

-6.19%

Return on Assets

23.93%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

9.65%

Stock Overview

Market Cap

$8.73MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

109.13M

Volume

10.03K

Avg. Volume

11.77K

Financials (TTM)

Gross Profit

-$1.27M

Operating Income

-$99.78M

EBITDA

$312.20M

Operating Cash Flow

$258.94M

Capital Expenditure

-$374.67K

Free Cash Flow

$258.56M

Cash & ST Invst.

$567.37M

Total Debt

$2.46M

LianBio Performance Analysis

LianBio annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
LianBio sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12023-03-31N/A
Q22023-06-30N/A
Q32023-09-30N/A
Q42023-12-31N/A
LianBio annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1.02-44.3%
20232023-12-31USD 2.87N/A
20242024-12-31USD 0.02-99.2%
20252025-12-31USD 0.0597.4%
LianBio sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12023-03-31-29.4%
Q22023-06-309.1%
Q32023-09-30-10.0%
Q42023-12-311713.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2023YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$347.00K

-9.8%

Gross Margin

0.00%

N/A

Market Cap

$8.73MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$53.56K

N/A

Employees

163

N/A

Net Income

$383.73M

+2199.7%

EBITDA

$383.30M

+2197.0%

Quarterly Fundamentals

Name
Q4 2023YOY CHG

Total Cash

$567.37M

+87.6%

Total Debt

$2.46M

-43.4%

Accounts Receivable

$39.91M

+805.0%

Inventory

$0.00

N/A

Long Term Debt

$511.00K

-79.5%

Short Term Debt

$1.95M

+5.1%

Return on Assets

23.93%

N/A

Return on Invested Capital

-6.19%

N/A

Free Cash Flow

$311.38M

+1096.4%

Operating Cash Flow

$311.52M

+1104.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
TXTMProText Mobility, Inc.
$0.00+10.53%
UNVCUnivec, Inc.
$0.00+0.00%
CUBTCurative Biotechnology, Inc.
$1.00+0.00%
INTIInhibitor Therapeutics, Inc.
$0.08+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$10.68+0.06%
UTZUtz Brands
$14.11+0.89%
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$35.46+0.25%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$40.30-0.06%

Questions About LIANY

What is the current price of LianBio?

LianBio is trading at $0.08 per share.

What is the 52-week range for LianBio?

Over the past 52 weeks, LianBio has traded between $0.05 and $0.18.

How much debt does LianBio have?

As of the most recent reporting period, LianBio reported total debt of $0.00.

How much cash does LianBio have on hand?

LianBio reported $9.39M in cash and cash equivalents in its most recent financial results.

What is LianBio’s dividend yield?

LianBio does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services